Intraoperative Hyperoxia and MINS

Sponsor
University Hospital Bispebjerg and Frederiksberg (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT04540276
Collaborator
Population Health Research Institute (Other)
7,700
8
36.8
962.5
26.1

Study Details

Study Description

Brief Summary

Oxygen therapy is administered to all patients during general anesthesia to maintain tissue oxygenation and prevent hypoxia and ischemia. However, liberal use of oxygen may lead to hyperoxia and some studies suggest that supranormal levels of arterial oxygen saturation may lead to complications. In this post hoc substudy of the VISION cohort, we plan to assess the association between perioperative inspired oxygen fraction (FiO2) and myocardial injury after non-cardiac surgery (MINS).

Condition or Disease Intervention/Treatment Phase
  • Drug: Inspiratory oxygen fraction

Detailed Description

Patients will be divided into five groups of median intraoperative FiO2 (quintiles), in which baseline characteristics and outcomes will be illustrated.

The odds ratio (OR) for the primary and secondary outcomes will be calculated in a logistic regression analysis with median FiO2 (continuous variable) as independent variable.

Analyses are performed with multiple logistic regression with adjustment for the following potentially confounding variables:

Age ≥75 years. Male sex. Current atrial fibrillation. History of diabetes. History of congestive heart failure. History of coronary artery disease. History of recent (i.e., < 6 months) high-risk coronary artery disease. History of stroke. History of peripheral vascular disease. History of hypertension. Preoperative eGFR (<30 vs. 30-44 vs. 45-59 vs. ≥60 mL/min/1.73m2). Low-risk surgery. Duration of surgery.

Study Design

Study Type:
Observational
Anticipated Enrollment :
7700 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Intraoperative Hyperoxia and MINS: A Post Hoc Analysis From the VISION Study Database
Actual Study Start Date :
Feb 4, 2018
Actual Primary Completion Date :
Oct 1, 2020
Anticipated Study Completion Date :
Mar 1, 2021

Outcome Measures

Primary Outcome Measures

  1. Myocardial injury after non-cardiac surgery (MINS) [Within 30 days after surgery.]

    Number of participants with MINS in the specified oxygen groups. MINS is defined as either ischemic troponin elevation or myocardial infarction after non-cardiac surgery.

Secondary Outcome Measures

  1. All-cause mortality [Within 30 days after surgery]

    Number of deaths within 30 days after surgery

  2. Myocardial infarction [Within 30 days after surgery]

    Number of participants with myocardial infarction within 30 days after surgery

  3. MINS [Within 30 days after surgery]

    Number of participants with MINS not fulfilling the fourth universal definition of myocardial infarction

  4. Rehospitalization for vascular reasons [Within 30 days after surgery]

    Number of participants rehospitalized for vascular reasons within 30 days after surgery

  5. Pneumonia [Within 30 days after surgery]

    Number of participants with pneumonia within 30 days after surgery

Other Outcome Measures

  1. Vascular mortality [Within 30 days after surgery]

    Number of vascular deaths within 30 days after surgery

  2. Non-fatal cardiac arrest [Within 30 days after surgery]

    Number of participants with non-fatal cardiac arrest within 30 days after surgery

  3. Cardiac revascularization procedure [Within 30 days after surgery]

    Number of participants undergoing cardiac revascularization procedure within 30 days after surgery

  4. Pulmonary embolism [Within 30 days after surgery]

    Number of participants with pulmonary embolism within 30 days after surgery

  5. New-onset clinically important atrial fibrillation [Within 30 days after surgery]

    Number of participants with new-onset clinically important atrial fibrillation within 30 days after surgery

  6. Peripheral arterial thrombosis [Within 30 days after surgery]

    Number of participants with peripheral arterial thrombosis within 30 days after surgery

  7. Severe sepsis or septic shock [Within 30 days after surgery]

    Number of participants with severe sepsis or septic shock within 30 days after surgery

  8. Surgical wound infection [Within 30 days after surgery]

    Number of participants with surgical wound infection defined as surgical incision infection or surgical abscess

  9. Deep venous thrombosis [Within 30 days after surgery]

    Number of participants with deep venous thrombosis within 30 days after surgery

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients entered in the VISION database, aged 18 years or above, undergoing noncardiac surgery in general anesthesia.
Exclusion Criteria:
  • Patients with unobtainable data on perioperative FiO2.

  • Patients with unobtainable data on postoperative troponin.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cleveland Clinic Cleveland Ohio United States 44195
2 Walter C. Mackenzie Health Sciences Centre Edmonton Canada
3 Prince of Wales Hospital Hong Kong China
4 Foundation CardioInfanil Bogotá Colombia
5 Bispebjerg Hospital Copenhagen NV Denmark 2400
6 Christian Medical College Ludhiāna India
7 University Malaya Medical Centre Kuala Lumpur Malaysia
8 Inkosi Albert Luthuli Hospital Durban South Africa

Sponsors and Collaborators

  • University Hospital Bispebjerg and Frederiksberg
  • Population Health Research Institute

Investigators

  • Principal Investigator: Christian S. Meyhoff, MD, PhD, University hospital Bispebjerg Frederiksberg
  • Study Chair: PJ Devereaux, MD, PhD, Population Healt Research Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sofie Pedersen, MD, PhD-student at Dept. of Anesthesia and Intensive Care, University Hospital Bispebjerg and Frederiksberg
ClinicalTrials.gov Identifier:
NCT04540276
Other Study ID Numbers:
  • Hyperoxia and MINS
First Posted:
Sep 7, 2020
Last Update Posted:
Feb 4, 2021
Last Verified:
Feb 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 4, 2021